Related Experiment Video
Updated: May 15, 2026
08:42
Using Multi-fluorinated Bile Acids and In Vivo Magnetic Resonance Imaging to Measure Bile Acid Transport
Published on: November 27, 2016
Colesevelam: a new and improved bile acid sequestrant?
Konstantinos Tziomalos1, Asterios Karagiannis, Dimitri P Mikhailidis
1First Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece. ktziomalos@yahoo.com
Current Pharmaceutical Design
|January 16, 2013
Summary
Colesevelam, a bile acid sequestrant, effectively lowers low-density lipoprotein cholesterol (LDL-C) in patients unable to reach targets with statins. It also improves glycemic control and is generally well-tolerated.
Area of Science:
- Cardiology and Endocrinology
- Pharmacology
Background:
- Statins are crucial for cardiovascular prevention but many patients do not achieve low-density lipoprotein cholesterol (LDL-C) targets.
- Patient statin intolerance or inability to reach therapeutic LDL-C levels necessitates alternative treatments.
Purpose of the Study:
- To evaluate colesevelam as a treatment option for patients with hyperlipidemia who are statin-intolerant or have not reached LDL-C goals.
Main Methods:
- Review of studies on colesevelam's efficacy and safety in managing LDL-C levels.
- Assessment of colesevelam's impact on glycemic control and patient tolerability.
Main Results:
- Colesevelam effectively reduces serum LDL-C levels.
- The drug demonstrates potential benefits in improving glycemic control.
- Short-term studies indicate favorable tolerability.
Conclusions:
- Colesevelam is a valuable therapeutic option for high-risk cardiovascular patients who cannot achieve LDL-C targets with statin monotherapy.
- Its dual action on LDL-C and glycemic control makes it a promising agent in lipid management.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:17Hepatic Drug Excretion: Enterohepatic Cycling
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
01:27Bioavailability Enhancement: Drug Permeability Enhancement
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
01:24Lipid Absorption
Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
01:16Hepatic Drug Excretion: Influencing Factors
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...